Marco Degidi1, Giuseppe Daprile1, Adriano Piattelli2. 1. Private Practice, Bologna, Italy. 2. Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.
Abstract
OBJECTIVES: The aims of the present cross-sectional study are to evaluate the bone remodeling around Morse-cone implants placed subcrestally 1 year after loading and the prevalence of bone loss >0.5 mm after at least 3 years of loading. MATERIAL AND METHODS: Subjects who underwent a radiographic check in 2013 with implants that had been in function for at least 3 years were considered for inclusion. The study population comprised of 145 subjects with a total of 523 implants. At the moment of insertion, all the implants were placed subcrestally from 1 to 3 mm as clinically measured. Radiographs taken at baseline, that is 1 year after loading (T0), and at the follow-up visit in 2013 (T1) were examined. The distance between the rim of the implant and the marginal bone level at mesial and distal aspects of each implant was determined and the mean bone loss calculated. RESULTS: In the total sample, the mean bone loss occurred between baseline and 2013 examination was 0.42 ± 0.77 mm; at T1 424 implants presented the marginal bone level at the implant rim (78) or above it (346). On the other hand, 99 implants presented the rim above the bone crest. Fifty-one implants that at T1 presented the rim above the bone crest, and that between T0 and T1 had lost at least 0.5 mm, were considered losers: 10 implants lost up to 0.5 mm, 11 lost from 0.6 to 1 mm, 16 lost from 1.1 to 2 mm, and 14 lost more than 2 mm of bone. On a subject basis, 34 subjects (group A) with a total of 200 implant sites presented loser implants, while 111 subjects (group B) with 323 implants displayed non-loser implants. CONCLUSIONS: Within the limits of a cross-sectional study, the results show that Morse-cone implants placed subcrestally in the vast majority of cases (89.9%) are able to maintain the bone crest at level of the rim or above it 1 year after loading. The incidence of loser sites (bone loss >0.5 mm) after at least 3 years of follow-up is 9.7% at implant level and 23.5% at patient level.
OBJECTIVES: The aims of the present cross-sectional study are to evaluate the bone remodeling around Morse-cone implants placed subcrestally 1 year after loading and the prevalence of bone loss >0.5 mm after at least 3 years of loading. MATERIAL AND METHODS: Subjects who underwent a radiographic check in 2013 with implants that had been in function for at least 3 years were considered for inclusion. The study population comprised of 145 subjects with a total of 523 implants. At the moment of insertion, all the implants were placed subcrestally from 1 to 3 mm as clinically measured. Radiographs taken at baseline, that is 1 year after loading (T0), and at the follow-up visit in 2013 (T1) were examined. The distance between the rim of the implant and the marginal bone level at mesial and distal aspects of each implant was determined and the mean bone loss calculated. RESULTS: In the total sample, the mean bone loss occurred between baseline and 2013 examination was 0.42 ± 0.77 mm; at T1 424 implants presented the marginal bone level at the implant rim (78) or above it (346). On the other hand, 99 implants presented the rim above the bone crest. Fifty-one implants that at T1 presented the rim above the bone crest, and that between T0 and T1 had lost at least 0.5 mm, were considered losers: 10 implants lost up to 0.5 mm, 11 lost from 0.6 to 1 mm, 16 lost from 1.1 to 2 mm, and 14 lost more than 2 mm of bone. On a subject basis, 34 subjects (group A) with a total of 200 implant sites presented loser implants, while 111 subjects (group B) with 323 implants displayed non-loser implants. CONCLUSIONS: Within the limits of a cross-sectional study, the results show that Morse-cone implants placed subcrestally in the vast majority of cases (89.9%) are able to maintain the bone crest at level of the rim or above it 1 year after loading. The incidence of loser sites (bone loss >0.5 mm) after at least 3 years of follow-up is 9.7% at implant level and 23.5% at patient level.
Authors: Matteo Albertini; Federico Herrero-Climent; Carmen María Díaz-Castro; Jose Nart; Ana Fernández-Palacín; José Vicente Ríos-Santos; Mariano Herrero-Climent Journal: Int J Environ Res Public Health Date: 2021-01-29 Impact factor: 3.390